

Paul B Koller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9014870/publications.pdf>

Version: 2024-02-01

20
papers

124
citations

1477746

6
h-index

1372195

10
g-index

20
all docs

20
docs citations

20
times ranked

161
citing authors

#	ARTICLE	IF	CITATIONS
1	Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. <i>Cancer</i> , 2022, 128, 529-535.	2.0	17
2	Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, 196, .	1.2	6
3	Clinical and immunologic responses to extracorporeal photopheresis and low-dose IL-2 in patients with steroid refractory chronic graft-versus host disease. <i>Bone Marrow Transplantation</i> , 2022, 57, 1045-1047.	1.3	4
4	A Clinical Review of the Different Strategies to Minimize Hemorrhagic Cystitis Associated with the Use of Post-Transplantation Cyclophosphamide in an Allogeneic Transplant. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 349-354.	0.6	4
5	Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL. <i>Blood Advances</i> , 2022, 6, 4936-4948.	2.5	7
6	<i>GATA3</i> rs3824662A allele in B-cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with <i>CRLF2</i> rearrangement and poor prognosis. <i>American Journal of Hematology</i> , 2021, 96, E71-E74.	2.0	5
7	High-Risk Mantle Cell Lymphoma in the Era of Novel Agents. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 8-18.	1.2	5
8	Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 255.e1-255.e9.	0.6	6
9	Outcomes in patients with <i>CRLF2</i> overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1746-1749.	1.3	5
10	Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (<sc>HMA</sc>) or liposomal daunorubicin+cytarabine (<sc>CPX</sc>+51). <i>American Journal of Hematology</i> , 2021, 96, E196-E200.	2.0	10
11	Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2464-2470.	1.3	8
12	A Phase 1a/b Dose Escalation Study of the Mutation Agnostic FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1272-1272.	0.6	5
13	Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias. <i>Blood</i> , 2021, 138, 3430-3430.	0.6	2
14	Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience. <i>Blood</i> , 2021, 138, 3037-3037.	0.6	0
15	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL. <i>Blood</i> , 2021, 138, 3955-3955.	0.6	0
16	Venetoclax and hypomethylating agents in <sc><i>FLT3</i></sc>-mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1193-1199.	2.0	28
17	Dasatinib Increases MHCII Surface Levels and Can Synergize with Anti-PD1 Therapy to Increase the Anti-Tumor Effect in a Pre-Clinical Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Model. <i>Blood</i> , 2020, 136, 44-44.	0.6	0
18	Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. <i>Cancer</i> , 2017, 123, 609-616.	2.0	4

#	ARTICLE	IF	CITATIONS
19	Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2015, 126, 1295-1295.	0.6	8
20	Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial. Blood, 2015, 126, 2508-2508.	0.6	0